At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,308 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Post Marketing Surveillance to Evaluate the Safety and Efficacy of Etanercept Under Usual Care Settings in Patients With Psoriatic Arthritis (PsA) Treated by Rheumatologists
In Brief
An observational study evaluating Etanercept for Arthritis, Psoriatic and 2 related conditions. Completed, enrolled 1,308 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of etanercept under usual care settings in patients with PsA treated by rheumatologists.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedFeb 2006
Primary CompletionFeb 2013
TodayJul 2026
First PostedFeb 17, 2006
Enrollment StartJan 1, 2006
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 20.4 years ago
Interventions
Etanerceptdrug
The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.